2025人工智能日

This slide presentation includes forward-looking statements Thispresentationcontainsforward-lookingstatementswithinthemeaningofthePrivateSecuritiesLitigationReformActof1995,asamended.Insomecases,forward-lookingstatementscanbeidentifiedbyterminologysuchas“will,”“may,”“should,”“expects,”“intends,”“plans,”“aims,”“anticipates,”“believes,”“estimates,”“predicts,”“potential,”“continue,”orthenegativeofthesetermsorothercomparableterminology,althoughnotallforward-lookingstatementscontainthesewords.Theforward-lookingstatementsinthispresentationareneitherpromisesnorguarantees,andyoushouldnotplaceunduerelianceontheseforward-lookingstatementsbecausetheyinvolveknownandunknownrisks,uncertainties,andotherfactors,manyofwhicharebeyondBioNTech’scontrol;andwhichcouldcauseactualresultstodiffermateriallyfromthoseexpressedorimpliedbytheseforward-lookingstatements.Youshouldreviewtherisksanduncertaintiesdescribedundertheheading“RiskFactors”inBioNTech'sQuarterlyReportonForm6-KfortheperiodendedJune30,2025;andinsubsequentfilingsmadebyBioNTechwiththeSEC,whichareavailableontheSEC’swebsiteathttps://www.sec.gov/.Exceptasrequiredbylaw,BioNTechdisclaimsanyintentionorresponsibilityforupdatingorrevisinganyforward-lookingstatementscontainedinthispresentationintheeventofnewinformation,futuredevelopmentsorotherwise.Theseforward-lookingstatementsarebasedonBioNTech’scurrentexpectationsandspeakonlyasofthedatehereof. Furthermore,certainstatementscontainedinthispresentationrelatetoorarebasedonstudies,publications,surveysandotherdataobtainedfromthird-partysourcesandBioNTech’sowninternalestimatesandresearch.WhileBioNTechbelievesthesethird-partysourcestobereliableasofthedateofthispresentation,ithasnotindependentlyverified,andmakesnorepresentationastotheadequacy,fairness,accuracyorcompletenessof,anyinformationobtainedfromthird-partysources.Inaddition,anymarketdataincludedinthispresentationinvolvesassumptionsandlimitations,andtherecanbenoguaranteeastotheaccuracyorreliabilityofsuchassumptions.WhileBioNTechbelievesitsowninternalresearchisreliable,suchresearchhasnotbeenverifiedbyanyindependentsource.Thispresentationcontainsreferencestoourtrademarksandtotrademarksbelongtootherentities.Solelyforconvenience,trademarksandtradenamesreferredto,includinglogos,artworkandothervisualdisplays,mayappearwithoutthe®orTMsymbols,butsuchreferencesarenotintendedtoindicate,inanyway,thattheirrespectiveownerswillnotassert,tothefullestextentunderapplicablelaw,theirrightsthereto.Wedonotintendouruseordisplayofothercompanies’tradenamesortrademarkstoimplyarelationshipwith,orendorsementorsponsorshipofusby,anyothercompanies. Agenda BioNTech–Building a global immunotherapypowerhouse translating science into survival Prof. U. Sahin, M.D.K. Beguir 14:00Advancing a disruptive tech-bio company14:15Developing the future of AI at BioNTech InstaDeep–Delivering across the full AI stack 14:25Compute & model scalingA. Laterre14:35AI innovationB. Almeida, B. Guloglu15:00Data acquisition & refinementN. Lopez Carranza, Y. Ben Dhieb15:20ApplicationsC. Zhang, L. Walls, A. Delaunay, M. Rooney15:40AudienceQ&AProf. U. Sahin, M.D., K. Beguir Advancing a disruptivetech-bio company BioNTech’s AI capabilities with worldwide reach BioNTech–disruptive tech-bio company with pioneering technologies developed through full AIintegration Infectious diseasespipeline 7Clinical programsin high unmetneed indications In-housemanufacturing 4PlatformsincludingindividualizedmRNA andbispecificantibodies 5Billion doses distributed VisionBuilding a globalimmunotherapy powerhousetranslating science into survival We are uniquely positioned to combine approaches to transform cancer care Immunomodulators •Focus on thecritical IO pathways•Targeting different complementary pathwaysin cancer immunity cycle may promote adurable anti-tumor effect Targeted therapies mRNA cancerimmunotherapies •Precise and potent modalities forfast onsettumor reduction•ADC as potential “augmenters”ofimmunomodulators and mRNAcancer immunotherapies•Focus on HER2, HER3, TROP2, B7H3ADCs as combination partners •Eliminate polyclonal residualdisease with multi-antigenandindividualized approaches•Polyspecificactivityby targetingmultiple antigens at once•Establish long-lastingimmunological memory toprevent relapses We are uniquely positioned to combine approaches to transform cancer care Immunomodulators •Focus on thecritical IO pathways•Targeting different complementary pathwaysin cancer immunity cycle may promote adurable anti-tumor effect•BNT327 pumitamig Targeted therapies •Eliminate polyclonal residualdisease with multi-antigenandindividualized approaches•Polyspecificactivityby targetingmultiple antigens at once•Establish long-lastingimmunological memory toprevent relapses Pumitamig’ssynergistic targeting of PD-L1 and VEGF1 NSCLC IHC2 Local neutralization ofangiogenic andimmunosuppressiveVEGF-A effects Targeting the TME andblockade of PD-1/PD-L1signaling Next-generation bispecific can potentially expand the reach of IO ther